CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 126 enrolled
Drug / intervention
Mg Cldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02466087
NCT02466087Phase 3Completed

Role of Magnesium Supplementation in the Treatment of Depression

University of Vermont·interventional·Posted Jun 9, 2015·Updated May 8, 2019

In Brief

A Phase 3 clinical trial evaluating Mg Cl for Depression. Completed, enrolled 126 participants across 1 site.

Detailed Summary

The objective of this project is to test the hypothesis that magnesium supplementation will decrease depressive symptoms in adults. This study takes place over 12 consecutive weeks. While the investigators will follow the volunteers for the full 12 weeks volunteers will only take magnesium supplements for 6 consecutive weeks. Volunteers will be randomly assigned to start the supplement at week 1 or week 7. Volunteers will take two supplement two times a day for a total of 248 mg elemental magnesium daily in the form of magnesium chloride. This amount of magnesium is less than the tolerable upper limit of 350 mg per day. The supplements will be provided. Volunteers will be asked to maintain their normal diet for the 12 weeks of the study. The primary outcome measure is the PHQ-9 questionnaire, a validated measure of depression. Secondary measures include the GAD-7 for Anxiety and side effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 9, 2015
Enrollment StartMay 1, 2015
Primary CompletionMay 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.1 years ago

Interventions

Mg Cldrug

Four supplements a day for 6 weeks.